The acquisition closed on July 14, 2026 (SEC 8-K 2.01). Its last closing price was on July 13, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from July 1, 2026. Source: SEC 8-K 2.01
XOMA Royalty Corp XOMA
NasdaqSmall CapHealthcare
Final 13F Pro quality score
Final rank #284 of 2,856 · as of July 1, 2026TOP 10%
AI-extracted from the 10-Q filed 2026-05-12 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
XOMA's total income and revenues fell 23% YoY to $12.3M as a prior-year $4.0M Takeda milestone did not repeat, while the company agreed to be acquired by Ligand for $39.00/share (~$739M equity value) announced April 27, 2026.
Biggest Revenue Drivers
Income from purchased receivables under the EIR method$9.2M+52% YoY
Higher estimated income from VABYSMO, plus newly reliably-estimable MIPLYFFA cash flows
Income from purchased receivables under the cost recovery method$2.8M-50% YoY
Prior year included a $4.0M Day One MAA-filing milestone plus royalties; this quarter reflects OJEMDA royalties only
Biggest Revenue Drivers
Total revenue: $12.3M-23% YoY
Income from purchased receivables under the EIR method$9.2M+52% YoY
Higher estimated income from VABYSMO, plus newly reliably-estimable MIPLYFFA cash flows
Within Income from purchased receivables under the EIR method
Affitech (VABYSMO)$6.7M+15% YoY
Roche VABYSMO commercial payments under the Affitech CPPA
LadRx (MIPLYFFA)$2.3M
Reclassified to EIR method in Q4 2025 once Zevra sales data allowed reliable cash-flow estimation
Income from purchased receivables under the cost recovery method$2.8M-50% YoY
Prior year included a $4.0M Day One MAA-filing milestone plus royalties; this quarter reflects OJEMDA royalties only
Revenue from contracts with customers$0-100% YoY
Prior-year quarter included a $4.0M payment under the Takeda Collaboration Agreement that did not recur
Largest Expense Items
General and administrative$11.9M+46% YoY
Increases in salaries, lease expense, tax services, legal fees, stock-based compensation, and litigation costs from the Janssen lawsuit
Amortization of intangible assets$892K+64% YoY
Amortization of Pulmokine/seralutinib and BioInvent contract-based intangible assets
Research and development$49K-96% YoY
Prior year included pass-through licensing fees tied to a Takeda milestone and Kinnate KIN-3248 wind-down costs
Margins: The company swung from operating income of $5.9M in Q1 2025 to an operating loss of $0.5M in Q1 2026, as lower milestone/contract revenue combined with higher G&A (litigation, lease, tax and legal costs) outpaced growth in EIR-method royalty income.
Watch Items from the Filing
Three partners represented 54%, 22% and 19% of total income and revenues for the quarter, indicating high revenue concentration.
XOMA agreed to be acquired by Ligand for $39.00/share in cash (~$739.0M equity value) plus a CVR; deal expected to close Q3 2026 subject to stockholder and regulatory approval, with a $40.0M termination fee in specified circumstances.
Two portfolio Phase 3 assets recently missed endpoints: Rezolute's ersodetug (Dec 2025) and Gossamer Bio's seralutinib PROSERA trial (Feb 2026), though no impairment was recorded on related XOMA assets.
Merger CVR value depends entirely on the outcome of ongoing Janssen litigation over TREMFYA, which is still in early discovery; the CVR could expire worthless.
Revenue from contracts with customers dropped to zero from $4.0M a year ago, highlighting the lumpy, milestone-dependent nature of that revenue line.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Kosacz BarbaraReporting ownerDisposition to issuer · Jul 14, 2026
Limber Joseph MReporting ownerDisposition to issuer · Jul 14, 2026
About XOMA Royalty Corp (XOMA): stock profile, AI score and financials
Acquired by Ligand Pharmaceuticals Incorporated: XOMA Royalty Corp (XOMA) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on July 14, 2026 (SEC 8-K 2.01). Its last closing price was on July 13, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from July 1, 2026. XOMA Royalty Corp (XOMA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks XOMA using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q1 2026), XOMA Royalty Corp reports quarterly revenue of $12.3M, net income of $4.5M, an operating margin of -3.9%. Top institutional holders of XOMA by reported 13-F value include BVF, MORGAN STANLEY, FMR, based on the most recent SEC filings. XOMA trades on the Nasdaq exchange and files with the SEC under CIK 791908. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XOMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for XOMA Royalty Corp directly from SEC EDGAR.